1.原文連結(必須檢附)：
http://www.analystratings.com/2016/02/23/maxim-group-maintains-a-buy-rating-on-stellar-biotechnologies-2/432156/
2.原文內容：
(截取部份重點及翻譯)
美心集團 對Stellar Biotechnologie 維持買入評等 目標價17美元
Maxim Group Maintains a Buy Rating on Stellar Biotechnologies
By George Macdonald
In a report released yesterday, Jason McCarthy from Maxim Group maintained a
Buy rating on Stellar Biotechnologies (NASDAQ: SBOT), with a price target of
$17. The company’s shares closed yesterday at $5.84. ( 目標價17美元 個人評:
該股因美生技股回跌至5.84)
Mccarthy noted, “OBI Pharma (TAIPEI – 4174:TT – $552.00- NR), a consumer
of Stellar’s KLH, announced that the company’s KLH-based immune therapy
OBI-822/821 showed in a post-hoc analysis that a sub-group of patients
(that mounted immune responses) had a highly significant improvement in PFS
and overall survival (OS) is trending towards statistical significance.
The full data has not been released yet.”
麥卡錫說，台灣浩鼎生技是Stellar Biotechnologies KLH 的購買者，該公司旗下以
KLH 為載體蛋白的免疫療法
OBI822/821 顯示在事後比較檢定（Post hoc tests) 參與試驗的病人若能產生免疫抗體
反應的次族群病患在 無疾病惡化存活期 PFS(progression free survival)有高度顯著
意義的改善 總體存活率(OS)方面也呈現明顯的正面趨勢。完整的數據尚未發布。
Stellar Biotechnologies has an analyst consensus of Moderate Buy.
分析師的共識。恆星生技 適度買進
3.心得/評論(必需填寫)：
世人皆醉我獨醒? 難道只有我相信,雖然解盲沒有過關,
只要浩鼎參加美國ASCO年會,公布DATA後,仍有很大的機會直接跟美國FDA申請藥證?